Iconic Therapeutics is a subsidiary of Endpoint Health, specializing in the development of innovative therapies for acute and chronic inflammatory conditions, ophthalmic diseases, and oncology. Their research focuses on targeting tissue factor, a key factor in modulating cytokines and driving oncogenic processes, to provide potential treatments for conditions such as acute lung injury, vasculitis, age-related macular degeneration, and solid tumors.
With a strong scientific advisory board and partnerships with companies like Exelixis, Iconic Therapeutics is at the forefront of advancing novel antibody-drug conjugates and therapeutic options. Their commitment to scientific excellence and groundbreaking research positions them as a leading player in the field of targeted therapies for a range of debilitating diseases.
Generated from the website